Overview

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

Status:
Active, not recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients

Phase:

Phase 2

Details

Lead Sponsor:

Universitätsklinikum Hamburg-Eppendorf
University Hospital Tuebingen

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate
Lenalidomide
Thalidomide